discuss financial all representing you, thank and results. we third quarter us of the led $XX.X as quarter Thank Adanna, We're XXXX growth you year-over-year. pleased today our revenue XX% with million, for joining by
execution. as commercial the emergent was Our reflects improved trauma result hospital procedures. in operating scheduled the well environment improvement performance and This of continued strength in in stabilization improvement as
to you As and estimated and unscheduled These quarter, may across specific data information and our limitations account surgeon based and received assumptions. growth and hospitals categories: reps regarding last from estimates subject X revenue reporting of we primary trauma such, practice the procedure on and procedures. began data recall, as assumptions received are available and sales are emergent the
During grew prior in and that approximately the trauma procedures year. estimate percent mid-single-digit quarter, range versus represented XX% of the we emergent revenue the
a from a days results to referred emergent ER. the As within are or few either typically injuries present and a reminder, trauma These specialist an are initial generally following injury. by procedures initially in immediately that completed
first hospital began quarter, and XXXX. to During to scheduling procedure the of staffing half compared the of stabilization we see in
half compared in hospitals procedures Cancel year. approximately first third [ certain we these the see growth the Although to ] continue quarter total to to procedures also lower within also revenue. ASCs, cost and routine settings as half access of represent the such improved of procedures of
this XX% that year. estimate versus we the approximately grew During prior the category quarter,
scheduled by reconstruction is caused mastectomy, or patient nerve nerve seeking As relief condition surgical of defect are characterized following a the a a following reminder, breast generally reconstruction nerve a where procedures a in procedure. as procedures removal These maxofacial of procedures and of nerve of and provide demandable painful improved opportunity is and as neuroma category decompression. The this such patients. for reconstruction to the oral surgical outcomes life reflective quality growth include
backed trained programs built with the have and that patient connect and activation educate success supported with by data patients We solutions effective surgeons. compelling by education surgeon and clinical them
those to $XXX,XXX XX we as Our there into months. on going core in accounts accounts, greater footprint. are focused is believe Core be continues revenue opportunity than expand in deeper our growth where tremendous trailing with defined strategy to the
ended sales territory direct of surgeon During primarily We core products. strength sales to end cases believe an X a be and approach in of use productivity force adoption the of our increased by ago. up levels. of approximately second targeted over and and accounts X year the Revenues we XXX, sequentially. quarter from XXX prior revenues, year now our increase an evaluate third totaled increase XXX of the reps of representatives, from up We accounts represent growth revenue driven the the XX% expanded XX% gain core quarter, demonstrating will to deeper our of prior X% as and quarter continue total commercial with add to sales and their from ability and from additional quarters, execution of XX% our the can
of by strategic Earlier procedure approximately is revenue. that XX% update force a be our our continue this we Our of we product to innovation, of direct expect will sales to were sales total agencies driver and an the growth. represent year, long-term pleased provide and in key independent pillar supplemented on
including we women XX% to believe implant-based an train additional breast expansion summary, have but X more additional patients. will innovations expect our XX% could our goal technique an we and training specific than of to an all early now we announced to a across teams We and trained offering, apply had As to choose for in initially teams set surgical by XX reconstruction continue additional new teams a performing procedures, XXXX. reconstruction, which XX of of resensation who year-end
our nerve also solutions these locations We diversity cubital protection traumatic and portfolio nerve in injury these adequately approximately anatomical of that defects, the nerve announced carpal injuries. requires targeted market believe challenges. their $XXX crush the Optimizing the syndromes, a injuries repair nontransected and some innovation represents million We the specific of a outcomes patients including The category wide process. injury of aspects of unique address types and both to present and healing protection and for of covers range overall portfolio. nerve tunnel in of injuries other
happy protection as pleased we the August, national to HA+ of began Nerve nerve these a adoption Axoguard release, feedback of the help for that surgeon successful with engagement will we're HA+ to We're announce and and very more Axoguard a new products, integrate into they launch Following in confident patients Protector. nerve expand initial with We're HA+ that pilot Axoguard will had nerve the algorithm. products first protection the injuries.
be a healing a Additionally, the we're and product, Section X-plus as during of separation protection new will product XXX be matrix continuing branded tissue providing phase as the will critical This development the tissue product. a nerve regulated soft tissue barrier, injuries. and through of nerve the protection temporary resorbable functions
product Avive+ emergent remain We supporting treatment QX this surgical expect trauma of on and in pain. to the further XXXX. We will protection, launch strengthen track position in nerve our
Moving updates evidence. body on to growing and clinical of our
Over we've solution. the economics repair to evidence significant investments develop nerve performance, to years, our the clinical and made of safety, quality demonstrate utility
as expected. Our programs active progressing are clinical
events quarter, we the quarter, published the OMF of end peer-reviewed Journal across the recently Hand was which the have the found of in than authors and Surgery study analysis of XXth Surgery Hand RECON advanced Conference. demonstrated and as was recovery for Society publications was length of breast, to that trauma, As results, included In a gap over conduits American functional the superiority pain. online greater Both Annual in of returned the increased. the XXX degree presented the of and
X as We addition the group as important by patient This literature demonstrated OR to of allograft Nerve supplemented premier motor by data costs excited findings allograft role are to supporting being the all reduced clinical time reduced published discussed surgeons. surgeons. in These and of outcomes autograft see well this surgeon meta-analysis efficacy the believe morbidity that and Notably, the publications. play procedure publications level with autograft. especially an publications continue these adopter Advance and sensory were was compared and payer comparable. Graft and evidence to in decision-making, in as will middle We that the
to our Advanced and new Turning our Neuro for graft. BLA production facility
in preparation began growth This was quarter, the During our tissue which Xx submission. designed expansion. BLA we our facility, processing for long-term to the key provides APC represents a milestone state-of-the-art new and in current and capacity up for for third
quarter of We plan FDA We the first in pre-BLA will will begin approval process. where support XXXX, meeting first complete quarter we of in second the continue utilization in with XXXX. BLA to this request a and submission We in anticipate quarter. a modules submission process the rolling early believe the the first filing to the half
will regulatory we XXX tissue-based And Graft products from XX XXX reminder, biological market reference a As of with product products. as potential a of the exclusivity. complete a for believe BLA providing designated would importantly, the be years Avanos approval biosimilars transition Nerve Avance
continue anchored our innovation, in market and Looking focused of ahead, execution strategic remain adoption to data, development our drive to surgeon we initiatives commercial growth. on and executing the clinical strength
also to through longer-term delivering flow profitability. as sheet we're and continue across believe breakeven we business our operating be the Importantly, cash balance sufficient will leverage bridge and the
of highlights and call the review turn will I to Now financial Pete provide guidance. our to a Pete? over
